<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04177173</url>
  </required_header>
  <id_info>
    <org_study_id>5181/REG./KEMU/2017</org_study_id>
    <nct_id>NCT04177173</nct_id>
  </id_info>
  <brief_title>Methotrexate and Statins With Methotrexate Alone in the Treatment of Rheumatoid Arthritis</brief_title>
  <official_title>Comparison of Combination of Methotrexate and Statins With Methotrexate Alone as an Anti-inflammatory Agent in the Treatment of Rheumatoid Arthritis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Edward Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Edward Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to compare the efficacy of combination of Methotrexate and
      Statins with Methotrexate alone in the treatment of Rheumatoid Arthritis. It is hypothesized
      that adding statins to methotrexate for treatment of rheumatic arthritis will significantly
      suppress the disease activity as compared to methotrexate alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After approval from Board of Studies and IRB of King Edward Medical University, all patients
      fulfilling inclusion and exclusion criteria from out patient department and wards of Mayo
      Hospital Lahore will be selected and randomized to group A or group B by lottery method
      (using coin flipping method) with one group receiving combination of methotrexate and
      simvastatin and other group receiving simvastatin only. All patients will be given adequate
      dose of analgesics for pain relief. Informed consent will be obtained from the patient.
      Demographic information like name, age and sex, will also be obtained. DAS 28 scoring will be
      done at the time of presentation and will be noted. Patients will be followed at 1 month, 3
      month and at 6 month. At each follow up DAS 28(ESR) score will be calculated using DAS 28
      calculator. All this information will be recorded on predesigned proforma (attached).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Actual">December 14, 2018</completion_date>
  <primary_completion_date type="Actual">December 14, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of drugs defined by improvement in Disease Activity Score 28 (DAS28)</measure>
    <time_frame>6 months</time_frame>
    <description>In Rheumatoid arthritis, DAS28 values range from 2.0 to 10.0 while higher values mean a higher disease activity. A DAS 28 below the value of 2.6 is interpreted as Remission/improvement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Drug Reaction</measure>
    <time_frame>6 months</time_frame>
    <description>Adverse event reported against any of the intervention under study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>Simvastatin &amp; Methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methotrexate 10 mg once a week per oral for 6 months and Statins (Simvastatin) 20 mg once a day per oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methotrexate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methotrexate 10 mg once a week for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin 20 mg</intervention_name>
    <description>improvement of disease activity</description>
    <arm_group_label>Simvastatin &amp; Methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate 10 mg</intervention_name>
    <description>improvement of disease activity</description>
    <arm_group_label>Methotrexate</arm_group_label>
    <arm_group_label>Simvastatin &amp; Methotrexate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients between ages 18 years and above

          -  Gender- Both male and female

          -  Fulfilling 2010 ACR/EULAR criteria of Rheumatoid arthritis with active inflammatory
             disease defined by DAS 28 score &gt;2.6,

          -  Normal serum cholesterol level.

        Exclusion Criteria:

          -  Already diagnosed patients of Diabetes mellitus.

          -  Use of steroids greater than 4 weeks of duration or intra articular steroid injection
             within 4 weeks of study.

          -  Statin therapy in last three months.

          -  Statin intolerant patient.

          -  Elevated Creatinine Phosphokinase more than twice the upper limit of normal range.

          -  Diagnosed case of Chronic liver disease or abnormal liver functions (transaminases &gt; 2
             times the upper limit of normal range) before the start of treatment or during
             follow-up.

          -  High serum Creatinine level

          -  Pregnancy and breast feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rabia Rathore, FCPS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Hospital</name>
      <address>
        <city>Lahore</city>
        <state>Punjab</state>
        <zip>54000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <reference>
    <citation>Alam SM, Kidwai AA, Jafri SR, Qureshi BM, Sami A, Qureshi HH, Mirza H. Epidemiology of rheumatoid arthritis in a tertiary care unit, Karachi, Pakistan. J Pak Med Assoc. 2011 Feb;61(2):123-6.</citation>
    <PMID>21375157</PMID>
  </reference>
  <results_reference>
    <citation>Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, Aletaha D, van Riel PL. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009 Jun;68(6):954-60. doi: 10.1136/ard.2007.084459. Epub 2008 May 19.</citation>
    <PMID>18490431</PMID>
  </results_reference>
  <results_reference>
    <citation>Mowla K, Rajai E, Ghorbani A, Dargahi-Malamir M, Bahadoram M, Mohammadi S. Effect of Atorvastatin on the Disease Activity and Severity of Rheumatoid Arthritis: Double-Blind Randomized Controlled Trial. J Clin Diagn Res. 2016 May;10(5):OC32-6. doi: 10.7860/JCDR/2016/16538.7814. Epub 2016 May 1.</citation>
    <PMID>27437268</PMID>
  </results_reference>
  <results_reference>
    <citation>Das S, Mohanty M, Padhan P. Outcome of rheumatoid arthritis following adjunct statin therapy. Indian J Pharmacol. 2015 Nov-Dec;47(6):605-9. doi: 10.4103/0253-7613.169585.</citation>
    <PMID>26729950</PMID>
  </results_reference>
  <results_reference>
    <citation>Aoki C, Nakano A, Tanaka S, Yanagi K, Ohta S, Jojima T, Kasai K, Takekawa H, Hirata K, Hattori Y. Fluvastatin upregulates endothelial nitric oxide synthase activity via enhancement of its phosphorylation and expression and via an increase in tetrahydrobiopterin in vascular endothelial cells. Int J Cardiol. 2012 Apr 5;156(1):55-61. doi: 10.1016/j.ijcard.2010.10.029. Epub 2010 Nov 18.</citation>
    <PMID>21093076</PMID>
  </results_reference>
  <results_reference>
    <citation>Abeles AM, Marjanovic N, Park J, Attur M, Chan ES, Al-Mussawir HE, Dave M, Fisher MC, Stuchin SA, Abramson SB, Pillinger MH. Protein isoprenylation regulates secretion of matrix metalloproteinase 1 from rheumatoid synovial fibroblasts: effects of statins and farnesyl and geranylgeranyl transferase inhibitors. Arthritis Rheum. 2007 Sep;56(9):2840-53. Erratum in: Arthritis Rheum. 2007 Oct;56(10):3510. Al-Mussawir, Hayfez [corrected to Al-Mussawir, Hayf E].</citation>
    <PMID>17763406</PMID>
  </results_reference>
  <results_reference>
    <citation>Lazzerini PE, Lorenzini S, Selvi E, Capecchi PL, Chindamo D, Bisogno S, Ghittoni R, Natale MR, Caporali F, Giuntini S, Marcolongo R, Galeazzi M, Laghi-Pasini F. Simvastatin inhibits cytokine production and nuclear factor-kB activation in interleukin 1beta-stimulated synoviocytes from rheumatoid arthritis patients. Clin Exp Rheumatol. 2007 Sep-Oct;25(5):696-700.</citation>
    <PMID>18078616</PMID>
  </results_reference>
  <results_reference>
    <citation>Gazzerro P, Proto MC, Gangemi G, Malfitano AM, Ciaglia E, Pisanti S, Santoro A, Laezza C, Bifulco M. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev. 2012 Jan;64(1):102-46. doi: 10.1124/pr.111.004994. Epub 2011 Nov 21. Review.</citation>
    <PMID>22106090</PMID>
  </results_reference>
  <results_reference>
    <citation>Agrawal S, Misra R, Aggarwal A. Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clin Rheumatol. 2007 Feb;26(2):201-4. Epub 2006 Mar 30.</citation>
    <PMID>16572283</PMID>
  </results_reference>
  <results_reference>
    <citation>McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011 Dec 8;365(23):2205-19. doi: 10.1056/NEJMra1004965. Review.</citation>
    <PMID>22150039</PMID>
  </results_reference>
  <results_reference>
    <citation>Dowman B, Campbell RM, Zgaga L, Adeloye D, Chan KY. Estimating the burden of rheumatoid arthritis in Africa: A systematic analysis. J Glob Health. 2012 Dec;2(2):020406. doi: 10.7189/jogh.02.020406.</citation>
    <PMID>23289081</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>April 7, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>November 25, 2019</last_update_submitted>
  <last_update_submitted_qc>November 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King Edward Medical University</investigator_affiliation>
    <investigator_full_name>Rabia Rathore</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Methotrexate</keyword>
  <keyword>Statins</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

